Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Restrictive Use of Dexamethasone in Glioblastoma
NCT04266977Recruiting
- Sponsor
- Insel Gruppe
- Start
- May 2020
- Primary completion
- Apr 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of dexamethasone in glioblastoma (GBM), sponsored by Insel Gruppe. Primary endpoint: Failure rate of the restrictive DEX regimen at 30 days. Started May 2020; status: recruiting.
02
Drugs
dexamethasone
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04266977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04266977.